Company news: Pfizer, Novo Nordisk and Lundbeck

Share this article:

Pfizer said it will acquire privately held, specialty pharmaceutical company NextWave Pharmaceuticals for $255 million, with NextWave shareholders eligible to receive additional payments of up to $425 million based on certain sales milestones. NextWave, focused on products for treating ADHD and related CNS disorders, markets Quillivant XR (methylphenidate hydrochloride), a once-daily liquid ADHD medication approved in September. Pfizer entered into an option and merger agreement with NextWave during second-quarter 2012 and made an option payment of $20 million. Pfizer is now exercising its option to acquire the company. Deal terms call for Pfizer to pay $255 million to NextWave shareholders at the close of the transaction, expected during the fourth quarter subject to regulatory approval. Shareholders are eligible to receive additional payments of up to $425 million based on certain sales milestones.

NovoNordisk's ultra long-acting insulins Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) won positive recommendations from the  European Medicines Agency (EMA). Once-daily Tresiba has a duration of action beyond 42 hours, the company said. Ryzodeg can be administered once- or twice-daily. Financial analyst Soren Lontoft, of Sydbank, was quoted by Reuters as estimating peak annual sales of Tresiba at around 22 billion Danish crowns ($3.9 billion) worldwide and around 6 billion in Europe. An approval would challenge Sanofi's 10-year dominance in the long-acting insulin market, Lontoft, said, as quoted by Reuters. Both basal insulin products are headed for a review by US regulators on Nov. 8.

The EMA also rejected a treatment for Alzheimer's disease from Lundbeck called Acrescent, as studies presented did not present a clear benefit. The treatment combines two substances, memantine hydrochloride and donepezil hydrochloride, which already have approval in the EU as separate treatments, the EMA said.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies